agree it is the drugs and the data are key. The challenge is...

agree it is the drugs and the data are key.

The challenge is that we have 10 studies underway but we really have not had any consistent and timely release of meaningful results from these trials over the two and half years roughly. There is a gap between the need to ensure independence of trials but at the same time there needs to be timely transparency from these organizations/bodies. Otherwise you get what you have right now where largely small but sometimes even larger investors get impatient and sell which drives the price down artificially in my view. If there is no support, market just keeps this pressure on and we get what we are seeing now on both the Nasdaq and ASX with dry volume and price goes down especially at end of day on small trades. We need management to be much more active with the trial mangers to protect their independence but also share data more frequently at regular intervals.